GGrantIndex
Sort

261,768 grants matching gene therapy

Pathogenesis Informs Therapy for Glycosphingolipid and Glycoprotein Disorders

$1,155,231
Cynthia Tifft · National Human Genome Research Institute · ZIA · FY2023 · HG

BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORT

$1,155,061
Brigham And Women'S Hospital · R01 · FY2001 · CA

Immunobiology of Tolerance FF Allogeneic Hematopoietic Cell Transplantation

$1,155,049
John Andrew Hansen · Fred Hutchinson Cancer Research Center · P01 · FY2013 · AI

Translating a CSF delivered AAV9-SMN for treatment of Spinal Muscular Atrophy

$1,155,044
Brian K Kaspar · Research Inst Nationwide Children'S Hosp · U01 · FY2014 · NS

Mutational analysis of signal transducing gene families in malignant melanoma

$1,155,041
Yardena Samuels · National Human Genome Research Institute · ZIA · FY2009 · HG

Cancer Biology and Genetics

$1,155,009
Harold Varmus · National Human Genome Research Institute · ZIA · FY2015 · HG

Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML

$1,154,998
Jeffrey Wallace Tyner · Oregon Health & Science University · U54 · FY2020 · CA

Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML

$1,154,998
Jeffrey Wallace Tyner · Oregon Health & Science University · U54 · FY2021 · CA

Commercialization of cavitation-enhancing nanodroplets for DNA sample fragmentation in NGS applications

$1,154,747
Sandeep Kasoji · Triangle Biotechnology, Inc. · R44 · FY2021 · CA

Safety and Efficacy Testing of FX101 in an SIV/NHP Model

$1,154,643
Heidi A Kay · Jericho Sciences, Llc · R44 · FY2017 · MH

Center for Neurovisceral Sciences & Women's Health

$1,154,613
Emeran A Mayer · University Of California Los Angeles · P50 · FY2010 · DK

QC and Release Testing of Vector and Cell Clinical Gene Therapy Products

$1,154,517
Rachel Beyer · Division Of Basic Sciences - Nci · ZIC · FY2025 · CA

Identification and use of T-cell receptors recognizing common tumor mutations

$1,154,442
James C Yang · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA

Histidine phosphorylation as a new target for cancer therapy

$1,154,400
Tony R. Hunter · Salk Institute For Biological Studies · R35 · FY2020 · CA

Histidine phosphorylation as a new target for cancer therapy

$1,154,400
Tony R. Hunter · Salk Institute For Biological Studies · R35 · FY2025 · CA

Histidine phosphorylation as a new target for cancer therapy

$1,154,400
Tony R. Hunter · Salk Institute For Biological Studies · R35 · FY2022 · CA

Autologous T-cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in patients with Generalized Myasthenia Gravis (MG)

$1,154,358
Metin Kurtoglu · Cartesian Therapeutics, Inc. · R44 · FY2021 · NS

Epigenetic strategies for the in vitro generation of replacement beta cells

$1,154,087
Maike Sander · University Of California, San Diego · U01 · FY2013 · DK

Long-Term Neural Determinants of Cardiovascular Diseases

$1,154,053
John W Osborn · University Of Minnesota · R01 · FY2009 · HL

Novel 5-HT2A/mGluR5 Antagonist for Opioid Use Disorder

$1,153,945
Frederick Gerard Moeller · Virginia Commonwealth University · UG3 · FY2025 · DA

Histidine phosphorylation as a new target for cancer therapy

$1,153,906
Tony R. Hunter · Salk Institute For Biological Studies · R35 · FY2021 · CA

Center for Narcolepsy and Related Disorders (P50)

$1,153,883
Emmanuel J Mignot · Stanford University · P50 · FY2014 · NS

NADPH Oxidases as Novel Targets for Cancer Therapy

$1,153,863
James Doroshow · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

The Unfolded Protein Response in Cancer

$1,153,823
Constantinos Koumenis · University Of Pennsylvania · P01 · FY2013 · CA

International Research in Korea: Clinical Studies of Drug-Resistant Tuberculosis

$1,153,780
Clifton Barry · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI